Evaluation of Ischemia-modified Albumin and C-reactive Protein in Type 2 Diabetics with and Without Ketosis

Overview

Journal Biomark Insights

Publisher Sage Publications

Date 2012 Mar 24

PMID 22442627

Citations 7

Authors

Shao-Gang Ma

Yao Jin

Wen Hu

Feng Bai

Wen Xu

Wei-Nan Yu

Affiliations

Soon will be listed here.

Abstract

Overview: To investigate whether serum ischemia-modified albumin or C-reactive protein is reliable for predicting type 2 diabetic patients with ketosis.

Approach: One hundred and four diabetic patients, 48 with diabetic ketosis, and 33 controls were enrolled in the study. Serum ischemia-modified albumin and C-reactive protein were measured and evaluated for their ability to distinguish diabetic ketosis.

Results: Compared to the controls, the ischemia-modified albumin and C-reactive protein levels were higher in patients with diabetic ketosis and type 2 diabetes at the baseline. The levels of ischemia-modified albumin were higher in patients with type 2 diabetes than in the controls. C-reactive protein and ischemia-modified albumin levels were reduced after insulin treatment. The level of ischemia-modified albumin was an independent risk marker for diabetic ketosis (OR = 1.085, P = 0.008, 95% CI: 1.022-1.152). Receiver operating characteristic curves revealed that the areas under the curve were 0.917 for the modified albumin and 0.357 for C-reactive protein.

Conclusion: This study indicates that ischemia-modified albumin was significantly associated with diabetic ketosis and was more sensitive than C-reactive protein in reflecting diabetic ketosis.

Citing Articles

A systematic review and meta-analysis of ischemia-modified albumin in diabetes mellitus.

Zinellu A, Mangoni A Heliyon. 2024; 10(16):e35953.

PMID: 39224304 PMC: 11366936. DOI: 10.1016/j.heliyon.2024.e35953.

Association between disease activity and ischaemia-modified albumin in patients with ulcerative colitis.

Ipek S, Yalcin H, Toprak B Prz Gastroenterol. 2022; 17(3):203-206.

PMID: 36127943 PMC: 9475480. DOI: 10.5114/pg.2021.109664.

RED CELL DISTRIBUTION WIDTH AND ACUTE COMPLICATIONS OF DIABETES.

Atalay H, Boyuk B, Ates M, Guzel S, Celebi A, Ekizoglu I Acta Endocrinol (Buchar). 2019; 14(4):514-519.

PMID: 31149305 PMC: 6516412. DOI: 10.4183/aeb.2018.514.

Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans.

Marrocco I, Altieri F, Peluso I Oxid Med Cell Longev. 2017; 2017:6501046.

PMID: 28698768 PMC: 5494111. DOI: 10.1155/2017/6501046.

Evaluation of Ischemia-Modified Albumin, Malondialdehyde, and Advanced Oxidative Protein Products as Markers of Vascular Injury in Diabetic Nephropathy.

Ahmad A, Manjrekar P, Yadav C, Agarwal A, Srikantiah R, Hegde A Biomark Insights. 2016; 11:63-8.

PMID: 27158221 PMC: 4854310. DOI: 10.4137/BMI.S39053.

References

Gabay C, Kushner I . Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340(6):448-54. DOI: 10.1056/NEJM199902113400607. View

Chen C, Tsai W, Lin P, Shiesh S . The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease. Clin Chem Lab Med. 2011; 49(11):1817-21. DOI: 10.1515/CCLM.2011.675. View

El-Mesallamy H, Suwailem S, Hamdy N . Evaluation of C-reactive protein, endothelin-1, adhesion molecule(s), and lipids as inflammatory markers in type 2 diabetes mellitus patients. Mediators Inflamm. 2007; 2007:73635. PMC: 1820618. DOI: 10.1155/2007/73635. View

Ma S, Xu W, Wei C, Wu X, Hong B, Wang Z . Role of ischemia-modified albumin and total homocysteine in estimating symptomatic lacunar infarction in type 2 diabetic patients. Clin Biochem. 2011; 44(16):1299-303. DOI: 10.1016/j.clinbiochem.2011.08.1136. View

Vantyghem M, Balduyck M, Zerimech F, Martin A, Douillard C, Bans S . Oxidative markers in diabetic ketoacidosis. J Endocrinol Invest. 2001; 23(11):732-6. DOI: 10.1007/BF03345062. View

Ukinc K, Eminagaoglu S, Ersoz H, Erem C, Karahan C, Hacihasanoglu A . A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocrine. 2009; 36(3):425-32. DOI: 10.1007/s12020-009-9236-5. View

Turedi S, Patan T, Gunduz A, Mentese A, Tekinbas C, Topbas M . Ischemia-modified albumin in the diagnosis of pulmonary embolism: an experimental study. Am J Emerg Med. 2009; 27(6):635-40. DOI: 10.1016/j.ajem.2008.05.002. View

Turedi S, Cinar O, Yavuz I, Mentese A, Gunduz A, Caner Karahan S . Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population. J Nephrol. 2010; 23(3):335-40. View

Bar-Or D, Lau E, Winkler J . A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med. 2000; 19(4):311-5. DOI: 10.1016/s0736-4679(00)00255-9. View

10.

Iwasaki Y, Hamamoto Y, Kawasaki Y, Ikeda H, Honjo S, Wada Y . Japanese cases of acute onset diabetic ketosis without acidosis in the absence of glutamic acid decarboxylase autoantibody. Endocrine. 2010; 37(2):286-8. DOI: 10.1007/s12020-009-9301-0. View

11.

Gidenne S, Ceppa F, Fontan E, Perrier F, Burnat P . Analytical performance of the Albumin Cobalt Binding (ACB) test on the Cobas MIRA Plus analyzer. Clin Chem Lab Med. 2004; 42(4):455-61. DOI: 10.1515/CCLM.2004.079. View

12.

Kazlauskaite R, Evans A, Mazzone T, Fogelfeld L . Ethnic differences predicting ketonuria in patients with Type 2 diabetes. J Diabetes Complications. 2005; 19(5):284-90. DOI: 10.1016/j.jdiacomp.2005.01.002. View

13.

Stentz F, Umpierrez G, Cuervo R, Kitabchi A . Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004; 53(8):2079-86. DOI: 10.2337/diabetes.53.8.2079. View

14.

Hyun E, Ramachandran R, Hollenberg M, Vergnolle N . Mechanisms behind the anti-inflammatory actions of insulin. Crit Rev Immunol. 2011; 31(4):307-40. DOI: 10.1615/critrevimmunol.v31.i4.30. View

15.

Papadakis M, Grunfeld C . Ketonuria in hospitalized patients with non-insulin-dependent diabetes mellitus. Diabetes Care. 1986; 9(6):596-600. DOI: 10.2337/diacare.9.6.596. View

16.

Bar-Or D, Curtis G, Rao N, Bampos N, Lau E . Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem. 2000; 268(1):42-7. DOI: 10.1046/j.1432-1327.2001.01846.x. View

17.

Apple F, Wu A, Mair J, Ravkilde J, Panteghini M, Tate J . Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005; 51(5):810-24. DOI: 10.1373/clinchem.2004.046292. View

18.

Piwowar A, Knapik-Kordecka M, Warwas M . Comparison of the usefulness of plasma levels of oxidatively modified forms of albumin in estimating kidney dysfunction in diabetic patients. Clin Invest Med. 2010; 33(2):E109. DOI: 10.25011/cim.v33i2.12349. View

19.

Jain S, Kannan K, Lim G . Ketosis (acetoacetate) can generate oxygen radicals and cause increased lipid peroxidation and growth inhibition in human endothelial cells. Free Radic Biol Med. 1998; 25(9):1083-8. DOI: 10.1016/s0891-5849(98)00140-3. View

20.

Dalton R, Hoffman W, Passmore G, Martin S . Plasma C-reactive protein levels in severe diabetic ketoacidosis. Ann Clin Lab Sci. 2003; 33(4):435-42. View